As phosphorylation sites of myosin RLC may represent a potential target for therapeutic interventions, we tested whether S15D and T160D phosphomimetic RLCs can rescue cardiomyopathy phenotypes in a mouse model of HCM, Tg-R58Q mice (29). Here, MYL2 is linked to cardiomyopathy.